Ufer Mike, Rane Anders, Karlsson Ake, Kimland Elin, Bergman Ulf
Division of Clinical Pharmacology, WHO Collaborating Centre for Drug Utilisation Research and Clinical Pharmacological Services, Karolinska Institute, Huddinge University Hospital, 14186, Stockholm, Sweden.
Eur J Clin Pharmacol. 2003 Mar;58(11):779-83. doi: 10.1007/s00228-003-0560-z. Epub 2003 Feb 22.
Many hospital-based studies throughout Europe have shown that a substantial number of children receive off-label prescribed drugs that lack marketing authorisation for paediatric use. Since information about the extent and characteristics of this prescribing pattern in paediatric primary health care is limited, we assessed the proportion of off-label drug prescribing for paediatric outpatients in a reference population of 350,000 children using a computerised prescription database. We also determined the adherence to a treatment guideline provided by the Stockholm county council as a quality of prescribing indicator.
All drugs prescribed for children younger than 16 years of age in the Stockholm county in the year 2000 were ranked by the number of prescription items. The retrospective, descriptive analysis was restricted to those drugs that accounted for 90% of total prescribing. We calculated the proportion of off-label drug prescribing for different age and therapeutic groups with respect to age, formulation and route of administration using the Swedish Physician's Desk Reference. The quality of prescribing was estimated as the proportion of prescription items corresponding to recommended drugs in the local treatment guideline Kloka Listan (The Wise List).
Among the 317 drugs accounting for 90% of total prescribing, 575,526 prescription items were identified with an average proportion of off-label and recommended drug prescribing of 20.7% and 60.5%, respectively. The off-label proportion was similar in various age groups but widely different between therapeutic groups being much higher for topical (70.4%) than for systemic (5.4%) drugs. The extent to which recommended drugs were prescribed also greatly varied between therapeutic groups irrespectively of the off-label proportion.
Off-label drug prescribing for paediatric outpatients is a common phenomenon. However, it mainly applied to topical drugs and was to a substantial extent recommended by the local treatment guideline. Thus, off-label prescribing might represent a more administrative rather than clinical problem in the paediatric outpatient setting.
欧洲许多基于医院的研究表明,大量儿童使用了未获儿科用药上市许可的非适应证处方药。由于关于儿科初级卫生保健中这种处方模式的范围和特征的信息有限,我们使用计算机化处方数据库评估了350,000名儿童参考人群中儿科门诊患者非适应证用药的比例。我们还确定了对斯德哥尔摩郡议会提供的治疗指南的遵循情况,以此作为处方质量指标。
2000年斯德哥尔摩郡为16岁以下儿童开具的所有药物按处方数量进行排序。回顾性描述性分析仅限于占总处方量90%的那些药物。我们使用《瑞典医师案头参考》计算了不同年龄和治疗组在年龄、剂型和给药途径方面的非适应证用药比例。处方质量以符合当地治疗指南《明智清单》(Kloka Listan)中推荐药物的处方数量比例来估计。
在占总处方量90%的317种药物中,共识别出575,526张处方,非适应证用药和推荐用药的平均比例分别为20.7%和60.5%。各年龄组的非适应证用药比例相似,但不同治疗组之间差异很大,局部用药(70.4%)远高于全身用药(5.4%)。无论非适应证用药比例如何,推荐药物的处方比例在不同治疗组之间也有很大差异。
儿科门诊患者的非适应证用药是一种常见现象。然而,它主要适用于局部用药,并且在很大程度上是由当地治疗指南推荐的。因此,在儿科门诊环境中,非适应证用药可能更多地是一个管理问题而非临床问题。